organ transplant

CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.

CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

Transplant Genomics offers a test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection.

The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.

The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.

The acquisition of OTTR Complete Transplant Management will enable CareDx to integrate the EMRs of patients at transplant centers with longitudinal patient surveillance data.